GCC
NVO

Guardian Capital (Canada)’s Novo Nordisk NVO Stock Holding History

Guardian Capital (Canada)’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,213
Closed -$1.07M – 186
2025
Q3 		$1.07M Sell
19,213
-198,452
-91% -$11.6M 0.03% 124
2025
Q2 		$15M Buy
217,665
+5,870
+3% +$399K 0.53% 51
2025
Q1 		$14.7M Buy
211,795
+343
+0.2% +$28.3K 0.58% 52
2024
Q4 		$18.2M Buy
211,452
+2,386
+1% +$258K 0.68% 45
2024
Q3 		$24.9M Sell
209,066
-792
-0.4% -$106K 0.91% 33
2024
Q2 		$30M Sell
209,858
-1,375
-0.7% -$182K 1.13% 27
2024
Q1 		$27.1M Sell
211,233
-225
-0.1% -$26.8K 0.95% 31
2023
Q4 		$21.9M Sell
211,458
-3,153
-1% -$312K 0.78% 35
2023
Q3 		$19.5M Sell
214,611
-32,475
-13% -$2.86M 0.73% 40
2023
Q2 		$20M Sell
247,086
-2,742
-1% -$224K 0.64% 42
2023
Q1 		$19.9M Sell
249,828
-2,778
-1% -$197K 0.63% 42
2022
Q4 		$17.1M Sell
252,606
-972
-0.4% -$57K 0.56% 45
2022
Q3 		$12.6M Sell
253,578
-500
-0.2% -$26.8K 0.43% 51
2022
Q2 		$14.2M Buy
254,078
+28,752
+13% +$1.6M 0.43% 55
2022
Q1 		$12.5M Buy
225,326
+462
+0.2% +$23.7K 0.24% 63
2021
Q4 		$12.6M Sell
224,864
-3,588
-2% -$194K 0.24% 65
2021
Q3 		$11M Buy
228,452
+27,376
+14% +$1.32M 0.23% 70
2021
Q2 		$8.42M Buy
201,076
+132
+0.1% +$5.12K 0.17% 77
2021
Q1 		$6.77M Buy
200,944
+18,042
+10% +$643K 0.11% 82
2020
Q4 		$6.39M Sell
182,902
-84
-0% -$2.9K 0.15% 74
2020
Q3 		$6.35M Sell
182,986
-5,944
-3% -$198K 0.17% 73
2020
Q2 		$6.19M Buy
188,930
+4,298
+2% +$137K 0.16% 69
2020
Q1 		$5.56M Buy
+184,632
New +$5.5M 0.17% 71
2019
Q1 		– Sell
-16,244
Closed -$374K – 193
2018
Q4 		$374K Sell
16,244
-549,940
-97% -$12.2M 0.01% 147
2018
Q3 		$13.3M Buy
566,184
+82,448
+17% +$2.01M 0.22% 61
2018
Q2 		$11.2M Sell
483,736
-27,266
-5% -$648K 0.19% 64
2018
Q1 		$12.6M Buy
511,002
+63,174
+14% +$1.66M 0.22% 64
2017
Q4 		$12M Buy
447,828
+55,502
+14% +$1.41M 0.18% 73
2017
Q3 		$9.45M Buy
392,326
+18,950
+5% +$428K 0.14% 93
2017
Q2 		$8.01M Buy
+373,376
New +$7.53M 0.13% 98
2016
Q1 		– Sell
-346,290
Closed -$10.1M – 207
2015
Q4 		$10.1M Buy
346,290
+67,282
+24% +$1.86M 0.19% 74
2015
Q3 		$7.57M Buy
279,008
+105,096
+60% +$2.98M 0.14% 78
2015
Q2 		$4.76M Buy
173,912
+37,462
+27% +$1.05M 0.08% 103
2015
Q1 		$3.64M Sell
136,450
-59,898
-31% -$1.38M 0.06% 111
2014
Q4 		$4.16M Buy
196,348
+77,934
+66% +$1.74M 0.07% 100
2014
Q3 		$2.82M Sell
118,414
-2,608
-2% -$60K 0.04% 112
2014
Q2 		$2.79M Sell
121,022
-2,200
-2% -$48.6K 0.04% 111
2014
Q1 		$2.81M Buy
+123,222
New +$2.63M 0.04% 108
2013
Q4 		– Sell
-49,260
Closed -$834K – 206
2013
Q3 		$834K Sell
49,260
-114,440
-70% -$1.92M 0.01% 151
2013
Q2 		$2.54M Buy
+163,700
New +$2.72M 0.04% 102

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Guardian Capital (Canada)'s NVO Position: Q4 2025 in Review

Guardian Capital (Canada) sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 19,213 shares — an estimated $1.07M sold.

Guardian Capital (Canada) first reported a position in NVO in Q2 2013 and held it in 40 quarters. The position peaked at $30M in Q2 2024. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Guardian Capital (Canada) reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Guardian Capital (Canada) sold 19,213 Novo Nordisk shares in Q4 2025, an estimated $1.07M.
  • Guardian Capital (Canada) first reported a position in Novo Nordisk in Q2 2013 and held it in 40 quarters.
  • Guardian Capital (Canada)'s Novo Nordisk position peaked at $30M in Q2 2024.
  • 1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Guardian Capital (Canada)'s 13F filing for Q4 2025, filed 18 Feb 2026.